Group 1 - The company Guokai Hengtai stated that as of October 20, 2025, the number of shareholders will be 17,405 [2]

Core Viewpoint - Guoke Hengtai, a leading medical device distribution service provider in China, was established on February 7, 2013, and went public on July 12, 2023, in Shenzhen Stock Exchange, focusing on medical device distribution and related professional services [1]. Group 1: Business Performance - In Q3 2025, Guoke Hengtai reported revenue of 5.353 billion, ranking 2nd out of 50 in the industry, surpassing the industry average of 1.379 billion and the median of 0.755 billion, while the top competitor, Yingke Medical, achieved revenue of 7.425 billion [2]. - The net profit for the same period was 73.27 million, ranking 27th out of 50, below the industry average of 183 million and the median of 75.88 million, with the leading company, Lepu Medical, reporting a net profit of 996 million [2]. Group 2: Financial Ratios - As of Q3 2025, Guoke Hengtai's debt-to-asset ratio was 59.50%, a decrease from 63.79% in the previous year but still above the industry average of 23.66% [3]. - The gross profit margin for Q3 2025 was 10.08%, slightly down from 10.35% year-on-year and significantly lower than the industry average of 48.78% [3]. Group 3: Executive Compensation - The chairman, Liu Bing, received a salary of 2.769 million in 2024, an increase of 473,100 from 2.296 million in 2023 [4]. - The general manager, Xiao Wei, earned 1.9887 million in 2024, up by 347,700 from 1.641 million in 2023 [4]. Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 2.47% to 17,200, while the average number of circulating A-shares held per account increased by 2.54% to 18,800 [5].

北京市中伦律师事务所 关于国科恒泰（北京）医疗科技股份有限公司 2025 年第四次临时股东大会的 法律意见书 二〇二五年十月 法律意见书 目 录 | | 本次股东大会的召集、召开程序 . | | --- | --- | | | 出席本次股东大会人员和会议召集人资格 . | | 11 | 本次股东大会的表决程序和表决结果 . | | 四、 | 结论意见 6 | 2025 年第四次临时股东大会的 法律意见书 致：国科恒泰（北京）医疗科技股份有限公司 北京市中伦律师事务所（以下简称"本所"）受国科恒泰（北京）医疗科技 股份有限公司（以下简称"公司"）委托，指派律师见证公司 2025 年第四次临时 股东大会（以下简称"本次股东大会"）。本所律师根据《中华人民共和国公司法》 （以下简称"《公司法》"）等相关法律、法规、规范性文件及《国科恒泰（北京） 医疗科技股份有限公司章程》（以下简称"《公司章程》"）的规定，对本次股东 大会进行见证并出具法律意见。 本所及经办律师依据《中华人民共和国证券法》《律师事务所从事证券法律 业务管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定及本法 律意见书出具日以前已经发生或者 ...

证券代码：301370 证券简称：国科恒泰 公告编号：2025-068 国科恒泰（北京）医疗科技股份有限公司 2025 年第四次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会不存在否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 现场会议时间：2025 年 10 月 31 日（星期五）下午 14:30 网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为：2025 年 10 月 31 日上午 9:15-9:25，9:30-11:30 和下午 13:00-15:00；通过深圳证券交易所 互联网系统投票的具体时间为：2025 年 10 月 31 日上午 9:15 至下午 15:00 的任意 时间。 2、会议召开地点：北京市北京经济技术开发区经海四路 25 号 6 号楼公司 410 会议室。 3、会议召开方式：本次股东大会采取现场投票与网络投票相结合的方式。 一、会议的召开和出席情况 （一）会议的召开情况 1、会议的召开时间： 4、会议召集人：公司第三届董事会。 5、会议主持人：董事长 ...

Core Viewpoint - Guoke Hengtai (Beijing) Medical Technology Co., Ltd. reported its financial results for the third quarter of 2025, indicating a challenging environment in the high-value medical consumables market due to accelerated procurement and price reductions [1][2]. Financial Performance - In the first three quarters of the year, the company achieved operating revenue of 5.353 billion yuan and a net profit attributable to shareholders of 67.3565 million yuan [1]. - For the third quarter alone, the company reported operating revenue of 1.675 billion yuan and a net profit attributable to shareholders of 15.261 million yuan [2]. Industry Insights - The high-value medical consumables market in China is under significant pressure due to accelerated coverage of volume-based procurement and price reductions, leading to a slowdown in overall industry growth [2]. - The demand for high-value medical consumables, particularly in orthopedics and cardiovascular sectors, is expected to increase as the aging population grows and policy impacts gradually clear [2].

Core Viewpoint - Guokai Hengtai (301370.SZ) reported a decline in both revenue and net profit for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The company's operating revenue for the first three quarters was 5.353 billion yuan, a year-on-year decrease of 2.30% [1] - The net profit attributable to shareholders of the listed company was 67.3565 million yuan, representing a year-on-year decrease of 32.49% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 57.7159 million yuan, down 40.96% year-on-year [1] - Basic earnings per share were 0.14 yuan [1]

证券代码：301370 证券简称：国科恒泰 公告编号：2025-067 国科恒泰（北京）医疗科技股份有限公司 第三届监事会第二十五次会议决议公告 2、本次会议于 2025 年 10 月 27 日以现场与通讯相结合的方式召开。 3、本次会议由监事会主席何志光先生召集并主持，会议应出席监事 5 名， 实际出席监事 5 名（其中监事何志光、仇连勇以通讯方式参加会议）。与会监事 以记名投票表决方式对会议审议议案进行了表决。 本公司及监事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 4、本次监事会会议的召集、召开和表决程序符合《中华人民共和国公司法》 等法律、法规及《公司章程》的有关规定，合法有效。 二、监事会会议审议情况 与会监事对本次会议需审议的议案进行了充分讨论，审议通过了以下议案： 1、审议通过《关于<2025 年第三季度报告>的议案》 经审核，监事会认为：公司《2025 年第三季度报告》相关内容的编制和审核 程序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反 映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 公 ...

证券代码：301370 证券简称：国科恒泰 公告编号：2025-066 国科恒泰（北京）医疗科技股份有限公司 第三届董事会第四十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、国科恒泰（北京）医疗科技股份有限公司（以下简称"公司"）第三届 董事会第四十五次会议已于 2025 年 10 月 20 日通过电子邮件方式通知了全体董 事。 2、本次会议于 2025 年 10 月 27 日以现场与通讯相结合的方式召开。 4、本次董事会会议的召集、召开和表决程序符合《中华人民共和国公司法》 等法律、法规及《公司章程》的有关规定，合法有效。 二、董事会会议审议情况 经与会董事认真审议，充分讨论，审慎表决，会议审议通过了以下议案： 1、审议通过《关于<2025 年第三季度报告>的议案》 公司根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所创业板 上市公司自律监管指南第 2 号——公告格式：第 46 号上市公司季度报告公告格 式》等相关规定编制了《2025 年第三季度报告》。 公司《2025 年第三季度报告》的具体内容详见公 ...

Financial Performance - The company's revenue for Q3 2025 was ¥1,674,554,353.82, representing a decrease of 8.02% compared to the same period last year[5]. - Net profit attributable to shareholders for Q3 2025 was ¥15,261,028.68, down 58.58% year-on-year[9]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥10,298,811.06, a decline of 70.64% compared to the previous year[11]. - The basic and diluted earnings per share for Q3 2025 were both ¥0.03, reflecting a decrease of 66.67% from ¥0.09 in Q3 2024[9]. - Total operating revenue for the current period is ¥5,353,226,595.70, a decrease of 2.3% from ¥5,479,472,836.38 in the previous period[21]. - Net profit for the current period is ¥73,266,609.62, a decline of 26.9% compared to ¥100,187,565.39 in the previous period[23]. - Earnings per share for the current period is ¥0.14, down from ¥0.21 in the previous period[23]. Cash Flow and Liquidity - The net cash flow from operating activities for the first nine months of 2025 was ¥490,326,618.41, down 30.65% from ¥707,063,637.76 in the same period last year[10]. - Cash generated from operating activities is ¥6,140,694,388.48, a decrease from ¥6,376,867,755.75 in the previous period[24]. - Net cash flow from operating activities was $490.33 million, a decrease of 30.7% compared to $707.06 million in the previous period[25]. - Total cash inflow from operating activities was $7.89 billion, while cash outflow was $7.40 billion, resulting in a net increase of $490.33 million[25]. - The ending balance of cash and cash equivalents was $714.35 million, down from $868.64 million in the previous period[26]. - Cash received from tax refunds amounted to $1.75 billion, compared to $1.58 billion previously[25]. - Cash paid for employee compensation was $170.42 million, a slight decrease from $177.90 million in the previous period[25]. - Cash paid for taxes was $104.93 million, down from $128.26 million in the previous period[25]. Assets and Liabilities - Total assets at the end of Q3 2025 were ¥6,319,891,150.33, a decrease of 4.77% from the end of the previous year[5]. - The total assets of the company as of September 30, 2025, amounted to CNY 6,319,891,150.33, a decrease from CNY 6,636,569,329.88 at the beginning of the period[17]. - Current assets decreased from CNY 5,849,378,587.75 to CNY 5,505,997,878.68, reflecting a decline of approximately 5.86%[17]. - The company's total liabilities decreased from CNY 4,636,569,329.88 to CNY 4,319,891,150.33, reflecting a decrease of about 6.84%[17]. - Total liabilities amount to ¥3,760,412,120.93, down from ¥4,073,989,164.42 in the previous period[22]. - Total equity stands at ¥2,559,479,029.40, slightly down from ¥2,562,580,165.46 in the previous period[22]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 17,223[13]. - The largest shareholder, Dongfang Keyi Holdings, holds a 30.13% stake in the company[13]. - The equity attributable to shareholders at the end of Q3 2025 was ¥2,506,344,685.30, an increase of 1.19% from the previous year[5]. Operational Metrics - The company reported a significant decline in gross profit, which contributed to the decrease in net profit[9]. - Total operating costs for the current period are ¥5,254,415,583.98, down 1.9% from ¥5,354,912,218.48 in the previous period[22]. - The company reported a significant increase in other income to ¥6,683,689.24 from ¥1,687,365.75 in the previous period[22]. - The company experienced a rise in financial expenses, totaling ¥28,328,643.67 compared to ¥50,041,270.06 in the previous period[22]. - The company’s deferred income tax liabilities increased to ¥5,961,518.99 from ¥2,580,903.48 in the previous period[22]. Inventory and Receivables - Accounts receivable decreased from CNY 1,558,930,002.18 to CNY 1,492,181,605.80, a reduction of approximately 4.26%[18]. - Inventory decreased from CNY 2,708,459,897.69 to CNY 2,488,669,913.27, indicating a decline of about 8.11%[18]. - The company reported a significant increase in other receivables, which rose from CNY 188,086,486.40 to CNY 156,290,622.07, a decrease of approximately 16.91%[18]. Fixed and Non-Current Assets - The company's fixed assets decreased slightly from CNY 539,150,113.33 to CNY 519,220,711.92, a decline of about 3.70%[18]. - The company’s non-current assets increased from CNY 787,190,742.13 to CNY 813,893,271.65, reflecting an increase of approximately 3.41%[18]. Audit Status - The company’s third-quarter financial report was not audited[27].

Core Points - Guoke Hengtai (301370) reported that as of October 20, 2025, the number of shareholders is 17,405 [1]